These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601 [TBL] [Abstract][Full Text] [Related]
7. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials. Buti S; Bersanelli M Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416 [No Abstract] [Full Text] [Related]
8. Immune Checkpoint Therapy in Renal Cell Carcinoma. Lee CH; Motzer RJ Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903 [TBL] [Abstract][Full Text] [Related]
9. Pushing the limits of immune-related response: a case of "extreme pseudoprogression". Wong AS; Thian YL; Kapur J; Leong CN; Kee P; Lee CT; Lee MB Cancer Immunol Immunother; 2018 Jul; 67(7):1105-1111. PubMed ID: 29728723 [TBL] [Abstract][Full Text] [Related]
10. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy. Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356 [TBL] [Abstract][Full Text] [Related]
12. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition]. Oppel-Heuchel H; Grimm MO Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870 [TBL] [Abstract][Full Text] [Related]
13. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
14. [Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer]. Jacquin-Porretaz C; Nardin C; Puzenat E; Roche-Kubler B; Aubin F; Presse Med; 2017 Sep; 46(9):808-817. PubMed ID: 28683958 [TBL] [Abstract][Full Text] [Related]
16. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. Weinstock M; McDermott DF Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188 [TBL] [Abstract][Full Text] [Related]
17. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321 [TBL] [Abstract][Full Text] [Related]
18. Imaging in metastatic renal cell carcinoma. Griffin N; Gore ME; Sohaib SA AJR Am J Roentgenol; 2007 Aug; 189(2):360-70. PubMed ID: 17646462 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183 [TBL] [Abstract][Full Text] [Related]
20. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. Brayer J; Fishman M J Immunother; 2014 Apr; 37(3):187-91. PubMed ID: 24598453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]